tirzepatide fda approval for weight loss Day 4: Zepbound (Tirzepatide – indication) Approved: November 2023 weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management Tirzepatide 5mg | FDA-Approved Diabetes

A slight majority of current users are still exercising at a gym at least once per month

The tirzepatide has substantially cleared, but the semaglutide has not yet reached full steady-state concentration

Engaging with healthcare providers to explore these choices can empower individuals to make informed decisions that align with their aspirations and circumstances

The response rate proved equally impressive: 91.7% of participants at the 12mg dose achieved at least 10% weight loss, and the majority achieved 15% or greater

Still, the exact processes behind these effects are poorly understood, and studies in humans are limited